Onward Medical N.V. (ONWD.BR)
EUR 4.02
(5.24%)
EUR 4.02
(5.24%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16.3 Million EUR | 16.89% |
| 2022 | 13.95 Million EUR | 5.75% |
| 2021 | 13.19 Million EUR | -68.5% |
| 2020 | 41.87 Million EUR | 24.35% |
| 2019 | 33.67 Million EUR | 92.79% |
| 2018 | 17.46 Million EUR | 64.58% |
| 2017 | 10.61 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 16.76 Million EUR | 0.0% |
| 2024 Q1 | 16.02 Million EUR | 5.03% |
| 2023 Q4 | 16.3 Million EUR | 0.0% |
| 2023 Q1 | 15.36 Million EUR | 10.16% |
| 2023 FY | 16.3 Million EUR | 16.89% |
| 2023 Q3 | 16.3 Million EUR | 6.11% |
| 2023 Q2 | 15.36 Million EUR | 0.0% |
| 2022 Q3 | 13.95 Million EUR | 2.88% |
| 2022 Q2 | 13.55 Million EUR | 0.0% |
| 2022 Q4 | 13.95 Million EUR | 0.0% |
| 2022 Q1 | 13.55 Million EUR | 2.78% |
| 2022 FY | 13.95 Million EUR | 5.75% |
| 2021 Q4 | 13.19 Million EUR | 0.0% |
| 2021 FY | 13.19 Million EUR | -68.5% |
| 2021 Q3 | 13.19 Million EUR | -80.97% |
| 2021 Q2 | 69.31 Million EUR | 0.0% |
| 2021 Q1 | 69.31 Million EUR | 65.51% |
| 2020 Q4 | 41.87 Million EUR | 0.0% |
| 2020 Q3 | 41.87 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 41.87 Million EUR | 24.35% |
| 2019 FY | 33.67 Million EUR | 92.79% |
| 2018 FY | 17.46 Million EUR | 64.58% |
| 2017 FY | 10.61 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nicox S.A. | 25.15 Million EUR | 35.173% |
| European Medical Solutions | 12.71 Million EUR | -28.232% |
| FERMENTALG | 14.33 Million EUR | -13.726% |
| argenx SE | 15.35 Million EUR | -6.2% |
| BioSenic S.A. | 15.57 Million EUR | -4.707% |
| Celyad Oncology SA | 902 Thousand EUR | -1707.761% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -4640.116% |
| Oxurion NV | 117 Thousand EUR | -13836.752% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -131.949% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.433% |